Karyopharm Therapeutics Inc. (KPTI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 108 | 210 | 157 | 146 | 145 | 146 | 147 | 136 |
| Operating profit | $m | -91 | -82 | ||||||
| Net profit | $m | -196 | -124 | -165 | -143 | -76 | -196 | -225 | - |
| EPS reported | $ | -17.93 | -13.07 | ||||||
| Operating cashflow per share | $ | -6.89 | -2.26 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -6.89 | -2.26 | ||||||
| Free cash flow | $m | -75 | -65 | ||||||
| Net debt | $m | 163 | 145 | ||||||
| Book value equity | $m | -293 | -330 | ||||||
| Book value per share | $ | -26.79 | -11.41 | ||||||
| Number of shares | m | 10.94 | 28.94 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.27 | -0.24 | ||||||
| P/S LTM | x | 0.55 | 0.55 | ||||||
| P/FCF LTM | x | -1.07 | -1.23 | ||||||
| EV/EBITDA LTM | x | -1.69 | -1.44 | ||||||
| EV/Sales LTM | x | 1.74 | 1.41 | ||||||
| Earnings Yield LTM | % | -2.44% | -3.84% | ||||||
| FCF Yield | % | -93.65% | -81.19% | ||||||
| Quality | |||||||||
| ROE | % | +66.92% | +77.63% | ||||||
| ROIC | % | -2.37% | +3.77% | ||||||
| Operating margin | % | -62.10% | -56.17% | ||||||
| Gross margin | % | +95.93% | +95.88% | ||||||
| FCF/Sales | % | -51.60% | -44.57% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +0.57% | +0.95% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.32 | -0.30 | ||||||
| Net Debt/EBITDA | x | -1.15 | -1.43 | ||||||
| EBIT/Net interest | x | -1.98 | -1.67 | ||||||
| Net debt/market cap | % | +2.82% | +4.58% | ||||||
| Net debt/Equity | x | -0.56 | -0.44 | ||||||
| Gross debt/equity | x | -0.80 | -0.65 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Karyopharm Therapeutics Inc. (KPTI)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free